P-007

P-007 is an investigational drug candidate being developed by Pangea Pharmaceuticals for the treatment of inflammatory conditions. Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development and commercialization of reformulated or generic versions of established therapies, often utilizing the 505(b)(2) regulatory pathway to provide improved therapeutic options. While the specific active pharmaceutical ingredient (API) and molecular target for P-007 have not been publicly disclosed, the candidate is part of a broader pipeline of products aimed at addressing unmet needs in cardiovascular, CNS, and inflammatory therapeutic areas. Given the company's portfolio, P-007 is likely a small molecule formulation intended to improve upon existing anti-inflammatory treatments.